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Abstract
Background: Whole exome sequencing (WES) has provided a means for researchers to gain access to a highly
enriched subset of the human genome in which to search for variants that are likely to be pathogenic and possibly
provide important insights into disease mechanisms. In developing countries, bioinformatics capacity and expertise
is severely limited and wet bench scientists are required to take on the challenging task of understanding and
implementing the barrage of bioinformatics tools that are available to them.
Results: We designed a novel method for the filtration of WES data called TAPER™ (Tool for Automated selection
and Prioritization for Efficient Retrieval of sequence variants).
Conclusions: TAPER™ implements a set of logical steps by which to prioritize candidate variants that could be
associated with disease and this is aimed for implementation in biomedical laboratories with limited bioinformatics
capacity. TAPER™ is free, can be setup on a Windows operating system (from Windows 7 and above) and does not
require any programming knowledge. In summary, we have developed a freely available tool that simplifies variant
prioritization from WES data in order to facilitate discovery of disease-causing genes.
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Background
Rapid developments in high throughput sequence cap-
ture methods as well as in next generation sequencing
(NGS) approaches have made whole exome sequencing
(WES) both technically feasible and cost-effective. More-
over, the success of WES in the discovery of novel
disease-causing mutations in numerous rare diseases is
well established [1, 2]. WES can typically yield tens of
thousands of variants per sequenced individual; the gen-
eration of data for analysis is therefore not considered to
be the challenge with WES or NGS, but rather the way
in which data is analysed is proving to be the major con-
undrum [3]. The identification of a single, plausible
disease-causing mutation for a particular disease is prov-
ing to be as difficult as looking for the proverbial “needle
in a haystack”. In addition to this, it has been well docu-
mented that every individual or pedigree will carry
several so-called private mutations that do not cause
overt disease [4]. Although numerous software tools are
available that can aid in the prioritization of candidate
disease-causing variants, all of the functionalities are dis-
seminated in various analytical tools and researchers are
forced to do all the analyses separately and then pool all
of the results together. This task is both time-consuming
and demands a considerable understanding of each of
the bioinformatics tools that are used [3, 5]. Moreover,
there are instances where different functional prediction
tools provide inconsistent results [5] thereby making it
exceptionally difficult to obtain a short list of candidates
for validation and further follow up studies.
Additionally, in developing countries the limited num-
ber of bioinformaticists and the lack of adequate compu-
tational infrastructure further limit the successful
application and implementation of NGS technologies. The
paucity of trained bioinformaticists means that wet bench
scientists with limited bioinformatics knowledge are left
with the daunting task of prioritizing candidate disease-
causing variants from files in a variant called format
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(VCF). Annotation of the data using programs such as
SeattleSeq (http://snp.gs.washington.edu/SeattleSeqAnno-
tation141/) or ANNOVAR [6] from the VCF file focus on
the comprehensive annotation of variants using informa-
tion from assorted bioinformatics resources which include
gene features, genomic conservation and possible patho-
genicity [3].
Accordingly, to meet these challenges we developed
TAPER™ (Tool for Automated selection and Prioritization
for Efficient Retrieval of sequence variants), which encom-
passes a number of steps to prioritize sequence variants
into one analytical procedure. TAPER™ has the potential
to empower researchers in resource-constrained environ-
ments and should enable them to generate a short list of
variants for further analyses. Moreover, we aim to do this
using a hypothesis-free approach whereby all information
(mathematical and statistical) is taken into account for
novel variant identification. TAPER™ can be used even
when the details of the phenotype, affection status and the
inheritance pattern are unclear. Additionally, we evaluated
the performance of TAPER™ through the use of a number
of proof-of-concept examples using four WES datasets
containing known causal mutations for three Mendelian
disorders. And finally, we compared TAPER to freely
available bioinformatics filtration pipelines namely PhenIX
[7] and Exomiser [8].
Implementation
TAPER™ is composed of a number of steps to filter
and prioritize candidate variants (single nucleotide
variants (SNVs) and indels) across individual patients
that have been subjected to WES. TAPER™ was con-
structed using Microsoft Visual Studio Professional
2013 (Microsoft Corporation, Microsoft Redmond
Campus, Redmond, Washington, United States) and add-
itional packages downloaded in order to support the
development of TAPER™ included Visual C#, CSV Helper
(http://joshclose.github.io/CsvHelper/) and HTML Agility
Pack (https://htmlagilitypack.codeplex.com/). It should be
noted that TAPER™ has been designed in such a way as to
filter all prioritized variants according to default settings.
Alternatively, the user is able to alter each parameter ac-
cording to their specific needs. The preliminary step in-
volves obtaining the raw, unaligned sequences in FASTQ
format. Quality control is then performed using FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/
) and aligned to the NCBI Human Reference Genome hg19
using NovoAlign v2 (http://www.novocraft.com/main/
page.php?s=novoalign). The outcome of the alignment file
is a VCF file, which is generated using the Mpileup function
in SAMTools (version 1.4). Submission of the aforemen-
tioned VCF file to wANNOVAR (http://wannovar.usc.edu/)
generates a downloadable text document, which is then in
turn, submitted to TAPER™. wANNOVAR is the online
version of the ANNOVAR, which is more user friendly for
those individuals who have limited or no command line ex-
perience. TAPER™ accommodates structured tab-delimited
text files and basic text files. Each of these formats can con-
tain annotation information as well as genotypes for nu-
merous samples. The seven-level filtration framework for
TAPER™ is illustrated in Fig. 1.
These seven steps can be explained as follows:
1. The submission of the processed.vcf files to an
online variant caller such as wANNOVAR (http://
wannovar.usc.edu/), allows for the annotation of
functional consequences of genetic variants from
high-throughput sequencing data. This procedure
is performed through an independent submenu in
TAPER™.
2. Removal of all synonymous variants as well as variants
that do not cause frameshifts – synonymous variations
are defined as codon substitutions that do not change
the amino acid and are unlikely to be the underlying
cause for rare diseases – for this reason these variants,
along with those that do not cause frameshifts, are
removed from the list of prioritized variants.
3. Removal of variants in the 1000 Genomes Project
(1KGP) (http://www.1000genomes.org/) that are
found at a frequency of greater than 1 % - any
variant that is found in the 1KGP database at a
frequency of 1 % or less is considered to be rare. It
is hypothesized that rare variants are likely to cause
disease and for this reason, variants with very low or
no available frequency data are prioritized.
4. Removal of variants in the Exome Sequencing
Project (ESP) 6500 (http://evs.gs.washington.edu/
EVS/) with a frequency of greater than 1 % - this
second frequency based step is based on that of the
1KGP data (STEP 3). Rare, possible disease-causing
variants are likely to be at an extremely low frequency
in this database and any variant with a frequency that
is higher than 1 % is removed from the list of interest.
5. Removal of variants with negative GERP scores –
Genomic Evolutionary Rate Profiling (GERP) scores
are the conservation scores from dbNSFP (database
for nonsynonymous SNPs functional predictions)
(http://sites.google.com/site/jpopgen/dbNSFP; [9];
higher scores are indicative of greater conservation;
scores of > 0 are considered to be conserved.
6. Removal all variants with positive FATHMM scores -
functional analysis through hidden Markov Models
(FATHMM) scores are used to determine the species-
specific weightings for the predictions of the functional
effects of protein missense variants [10]. The use of
FATHMM scores have been shown to outperform the
conventional prediction methods such as SIFT, Poly-
Phen2 and MutationTaster [10, 11]. Positive FATHMM
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scores predict a tolerance to the variation while nega-
tive FATHMM scores predict intolerance to the vari-
ation, and is subsequently considered to be pathogenic.
Following proof of concept analysis it was determined
that the best possible cut-off value for the FATHMM
score is 1.0.
7. Identification of associated disorders for prioritized
genes – the final step of TAPER™ determines whether
the genes of interest have been linked to any other
disorders using OMIM (Online Mendelian Inheritance
in Man) (http://www.omim.org/) database as well as
the DISEASES (http://diseases.jensenlab.org) database.
If any of these disorders are related or similar to the
disease of interest (e.g. both are brain disorders), then
that gene and variant will become the main candidate
for further analysis.
Results
Proof of concept experiments were conducted in order
to determine the efficacy of TAPER™. This was done on
existing processed WES data for which the disease-
causing gene had previously been identified using alter-
native methods. This was performed in order to deter-
mine whether or not the pipeline was effective as well as
to determine specific cut-off values for each of the param-
eters used. The datasets that were used were sourced from
various collaborators (Dr. Suzanne Lesage, Institut du
Creveau et de la Moelle épinière, Hôpital Pitié Salpêtrière,
Paris, France [12]; Mr Daniel J. Evans, Centre for Applied
Neurogenetics, University of British Columbia, Vancouver,
Canada) as well as files sourced from previously published
papers; the datasets used were those that previously iden-
tified variants in Parkinson’s disease as well as severe intel-
lectual disability and microcephaly and ataxia and
myoclonic epilepsy [13, 14]. Through the use of these
experiments, it was determined that the only filtration
parameter that was too stringent was the FATHMM score.
Adjusting the FATHMM score cut-off to 1.0 as opposed
to removing all variants with a positive FATHMM score,
allowed for the prioritisation of the four genes in each of
the datasets. However, due to its known high discrimina-
tive power, we recommend the standard cut-off of less
than -1.5 as the default TAPER™ starting point to ensure
broad utility across a diversity of exome studies. TAPER™
was therefore successfully used to identify the same vari-
ants that had previously been implicated in specific dis-
eases; FBOX7 (L34R) and PARK2 (R275W and M432V) in
Parkinson’s Disease (PD); SLC1A4 (E256K) in intellectual
disability and microcephaly and KCNA2 (R297Q) in ataxia
and myoclonic epilepsy (Table 1). In addition, we com-
pared the results obtained though TAPER™ when com-
pared to two other open source variant prioritization tools
(Additional file 1: Table S1). TAPER™ is a hypothesis-free
software package so no prior information regarding a par-
ticular disease is necessary. For each of the other software
packages used, a mode of inheritance as well as disease
STEP 7:  Identification of related disorders for prioritized genes (linking genes to specific 
disorders)
STEP 6:  Removal of all variants with FATHMM scores greater than 1.0
STEP5:  Removal of all variants with negative GERP+++ scores
STEP 4:  Removal of all variants in ESP6500 with a minor allele frequency of greater than 
1%
STEP 3:  Removal of all variants in 1KGP with a minor allele frequency of greater than 
1%
STEP2:  Removal of all synonymous and non-frameshift variants
STEP1:  Submission of VCF files to an online variant caller (for example wANNOVAR)
Fig. 1 The seven-level filtration framework that makes up the backbone of TAPER™. (Abbreviations: 1KGP – 1000 Genomes Project; ESP6500 – Exome
Sequencing Project 6500; GERP – Genomic Evolutionary Rate Prediction Score; FATHMM – Functional Annotation Through Hidden Markov Models)
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Table 1 Stepwise breakdown of results obtained by TAPER™ using WES datasets for which the causal mutations have previously been identified
Parkinson’s disease dataset 1 –FBOX7
(L34R) [12}
Intellectual disability and microcephaly
dataset 1 –SLC1A4 (E256K) [13}
Ataxia and myoclonic epilepsy
dataset 1 – KCNA2 (R297Q) [14}
Parkinson’s disease dataset 2 - PARK2
(R275W and M432V)
Individual_1 Individual_2 Individual_3 Individual_1 Individual_2 Individual_1 Individual_1 Individual_2 Individual_3
Total number of variants in VCF file 55 726 55 336 55 289 54 426 54 574 60 128 104 307 108 243 97 833
STEP 1: Total number of variants
assigned to exonic regions by
wANNOVAR
19 727 19 969 20 353 24 573 24 425 23 163 19 850 19 972 19 863
STEP 2: All synonymous and non-
frameshifts removed
9 465 9 544 9 766 12 227 12 248 11 693 9 752 9 777 9 838
STEP 3: Remove all variants with a
frequency >1 % in 1KGP
1 281 934 966 2 177 2 153 1 377 1 771 1 681 1 932
STEP 4: Remove all variants with a
frequency >1 % in ESP6500
917 797 819 1 928 1 906 941 1 335 1 445 1 575
STEP 5: Remove all variants with
negative GERP+++ scores
718 615 651 1 243 1 261 688 1 014 1 126 1 232
STEP 6: Remove all variants with
FATHMM scores greater than 1.0
262 224 240 252 231 257 413 301 328
STEP 7: Variants linked to relevant
diseases
252 221 236 241 221 239 398 262 292
Variant of interest in shortlist? Yes Yes Yes Yes Yes Yes Yes Yes Yes
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phenotypes are used to prioritize variants. This may gen-
erate a selection bias and for this reason, in small-scale la-
boratories where limited clinical information is available
pertaining to the patients, candidate variants may be lost
as a result of variant selection based on clinical features
and inheritance patterns.
Discussion
WES has provided a means for researchers to gain access
to a highly enriched subset of the human genome in which
to search for variants that are likely to be pathogenic and
possibly provide important insights into a particular disease.
TAPER™ was developed to support the need of biomedical
researchers and bioinformaticists alike. The aim behind
TAPER™ for the biomedical researcher is to provide an
environment that can be used to visualize and interpret
variation data that is obtained from WES sequencing plat-
forms. In addition, TAPER™ differs significantly from other
variant prioritization tools, as it does not require a hypoth-
esis driven approach. This means that phenotypic informa-
tion about the disease of interest as well as factors such as
inheritance patterns and knowledge of pathways are not
required to aid in variant prioritization. TAPER™ has appli-
cations in the broader sense When the outputs of TAPER™
are compared to those obtained from other software pack-
ages, TAPER™ generates a list of variants that is more man-
ageable due to smaller numbers and thereby making
variant selection for further analysis easier. This is illus-
trated when running the same datasets through other freely
available software such as PhenIX and Exomiser. PhenIX
ranks candidate variants based on variant pathogenicity as
well as phenotypic similarity of diseases associated with
genes harbouring these variants to the phenotypic profile of
the individual. PhenIX generated an average of 632 variants
per individual that was processed through this pipeline.
Data processed through the Exomiser is prioritized based
on variant frequency, inheritance patterns, phenotypic data,
pathogenicity and quality. For each of the datasets that were
processed through the Exomiser, an average of 816 candi-
date variants were obtained across the various individuals
(Additional file 1: Table S1). Moreover, for bioinformaticists
TAPER™ allows for VCF files that have been processed to
be given to the biomedical researcher, thereby allowing the
researcher to independently prioritize and interpret WES
results. TAPER™ is able to read pre-annotated variation data
from numerous file formats and allows users to search, sort
and sift through larger data set, whether by a predeter-
mined set of parameters or using each of TAPER™’s seven
functions independently. The efficiency and accuracy of
TAPER™ was tested using sets of data which contained
known pathogenic mutations – this allowed for the identifi-
cation of less stringent cut-off criteria which otherwise
would have allowed for the loss of possible disease-causing
variants. However, due to its known high discriminative
power we use the recommended FATHMM cut-off score
of less than 1.0 as a default starting point in TAPER™ to en-
sure broad utility and high predictive value. Overall,
TAPER™ will allow groups of researchers, particularly those
in resource constrained laboratories with very limited bio-
informatics capacity and resources, to interpret and analyse
sequence variation data, thereby making NGS technologies
such as WES more feasible in these laboratory setups.
Limitations of TAPER™
Given the general approach to WES data analysis through
TAPER™, one of the major limitations is the fact that
TAPER™ can only be used once a VCF file has already
been generated. This result means that a biomedical re-
searcher is still largely dependent on bioinformatics cap-
acity in order to perform quality control and sequence
alignment on samples that have been sequenced. This
may prove to be a significant limitation for small-scale
laboratories or in cases where bioinformatics capacity is
restricted. In addition to this, another limitation of the
TAPER™ program is the fact that cloud based storage is
not yet possible. TAPER™ is not yet able to upload filtered
results to data servers such as Dropbox (www.dropbox.-
com) or Google Drive (www.google.com/drive) – which
may become problematic with large numbers of sample
sets. Finally, TAPER™ can only be used on a Windows op-
erating system, which is limiting to individuals who may
use Linux or Macintosh (iOS) based systems.
Future Work
TAPER™ has been designed in such a way that the software
can later be amended to process different NGS data – this
will include whole genome sequencing, transcriptome ana-
lysis and targeted resequencing. It is anticipated that we will
include an additional filtration criteria, namely the use of
the ExAC Genome database (http://exac.broadinstitute.org/)
as this is the largest publically available database with exome
sequencing data. In addition to this, TAPER™ will be modi-
fied to provide an interactive and easy means for SAM and
BAM file conversions, conversion and merging of multiple
BAM files as well as to provide a local, fast way to
determine sequence coverage. We also intend to add an
additional submenu that will allow the user to perform
sequence manipulation – for example multiple se-
quence alignments, sequence assemblies and manipula-
tion as well as BLAST requests. This will make
TAPER™ a single software package that can be used for
multiple purposes by biomedical researchers with lim-
ited bioinformatics capacity.
Conclusion
NGS approaches such as WES have been able to provide
significant insights into human disease. In scientific
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environments where computational capacity as well as re-
sources are less restrictive, WES can provide much insight
but concurrently generate a massive “computational head-
ache”. Through the development of TAPER™, we have pro-
vided a single, easy to use, integrated approach to prioritize
specific variants that could be linked to a specific disease. It
is anticipated that as more researchers in developing coun-
tries move towards NGS and massively parallel sequencing,
TAPER™ provides a simple, intuitive tool that may help
highlight potential disease-causing variants.
Additional files
Additional file 1: Table S1. Results obtained from the comparison of
TAPER™ to two other whole exome sequencing data analysis tools.
(DOCX 18 kb)
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